Gloucester starts cancer combination therapy trial

Patients will receive bortezomib at a fixed standard dosing regimen and romidepsin at increasing doses in order to establish the most appropriate dose for each drug in this combination regimen. Once the appropriate dosage is determined, additional patients will be treated at that dosing regimen. The endpoints for this trial include both objective response and safety.

“Romidepsin appears to be a promising investigational drug and preclinical data indicate that the romidepsin and bortezomib combination is synergistic. It is our hope that the combination of romidepsin and bortezomib will prove beneficial to patients and we are pleased to initiate the first clinical trial of this combination in Australia,” said Miles Prince, chair of Clinical Cancer Services at the Peter MacCallum Cancer Centre.

Gloucester said it had ongoing trials in five hematologic and solid tumor indications, including registration trials in cutaneous T-cell lymphoma and peripheral T-cell lymphoma.